BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19201343)

  • 1. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.
    Monforte V; Ussetti P; López R; Gavaldà J; Bravo C; de Pablo A; Pou L; Pahissa A; Morell F; Román A
    J Heart Lung Transplant; 2009 Feb; 28(2):170-5. PubMed ID: 19201343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation.
    Monforte V; Ussetti P; Gavaldà J; Bravo C; Laporta R; Len O; García-Gallo CL; Tenorio L; Solé J; Román A
    J Heart Lung Transplant; 2010 May; 29(5):523-30. PubMed ID: 20061165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients.
    Monforte V; Roman A; Gavaldá J; López R; Pou L; Simó M; Aguadé S; Soriano B; Bravo C; Morell F
    Transplantation; 2003 May; 75(9):1571-4. PubMed ID: 12792517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients.
    Husain S; Capitano B; Corcoran T; Studer SM; Crespo M; Johnson B; Pilewski JM; Shutt K; Pakstis DL; Zhang S; Carey ME; Paterson DL; McCurry KR; Venkataramanan R
    Transplantation; 2010 Dec; 90(11):1215-9. PubMed ID: 20881664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.
    Monforte V; López-Sánchez A; Zurbano F; Ussetti P; Solé A; Casals C; Cifrian J; de Pablos A; Bravo C; Román A
    J Heart Lung Transplant; 2013 Mar; 32(3):313-9. PubMed ID: 23332731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.
    Peghin M; Monforte V; Martin-Gomez MT; Ruiz-Camps I; Berastegui C; Saez B; Riera J; Ussetti P; Solé J; Gavaldá J; Roman A
    Transpl Int; 2016 Jan; 29(1):51-62. PubMed ID: 26339864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B disposition after aerosol inhalation in lung transplant recipients.
    Marra F; Partovi N; Wasan KM; Kwong EH; Ensom MH; Cassidy SM; Fradet G; Levy RD
    Ann Pharmacother; 2002 Jan; 36(1):46-51. PubMed ID: 11816256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients].
    López-Medrano F; Díaz-Pedroche C; Lumbreras C; Aguado JM
    Rev Esp Quimioter; 2005 Mar; 18(1):14-20. PubMed ID: 15915227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome).
    Watanabe A; Matsumoto K; Igari H; Uesato M; Yoshida S; Nakamura Y; Morita K; Shibuya K; Matsubara H; Yoshino I; Kamei K
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e220-3. PubMed ID: 19959388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients.
    Conneally E; Cafferkey MT; Daly PA; Keane CT; McCann SR
    Bone Marrow Transplant; 1990 Jun; 5(6):403-6. PubMed ID: 2196098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of anti-fungal management in lung transplantation.
    Dummer JS; Lazariashvilli N; Barnes J; Ninan M; Milstone AP
    J Heart Lung Transplant; 2004 Dec; 23(12):1376-81. PubMed ID: 15607667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
    Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
    Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B in three lung transplant recipients. The Groningen Lung Transplantation Group.
    Mannes GP; van der Bij W; de Boer WJ
    J Heart Lung Transplant; 1995; 14(4):781-4. PubMed ID: 7578189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New dosing strategies for liposomal amphotericin B in high-risk patients.
    Ellis M
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():55-64. PubMed ID: 18430130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B in lung transplant recipients.
    Klepser ME
    Ann Pharmacother; 2002 Jan; 36(1):167-9. PubMed ID: 11816247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.